Growth hormone-releasing hormone analog · Also known as Geref, Sermorelin acetate, GRF 1-29
A synthetic peptide identical to the first 29 amino acids of naturally occurring GHRH. It stimulates the pituitary to produce growth hormone through the body's own feedback mechanisms, producing a more physiological GH profile than exogenous HGH.
Sermorelin (brand name Geref) was FDA-approved in 1997 for the diagnosis and treatment of growth hormone deficiency in children. It was withdrawn from the market in 2008 by the manufacturer for commercial reasons, not safety concerns. The FDA formally confirmed the withdrawal was not due to safety or effectiveness issues. Today, it is widely available through compounding pharmacies and used off-label for age-related GH decline in adults.
Sermorelin binds to GHRH receptors on the anterior pituitary gland, triggering the synthesis and secretion of endogenous growth hormone. Because it works through the body's natural regulatory axis, the hypothalamic-pituitary feedback loop remains intact, which means GH release is self-limiting and less likely to cause supraphysiological hormone levels.
Administered at bedtime, sermorelin amplifies the natural nocturnal GH surge. Over weeks of consistent use, patients may see improvements in body composition, sleep quality, skin elasticity, and recovery. Because it stimulates endogenous production rather than replacing it, the pituitary gland continues to function normally, and the risk of GH-related side effects is lower compared to exogenous HGH.
200 mcg/day subcutaneous at bedtime
Weeks 1-4200-500 mcg/day at bedtime
3-6 monthsMost side effects tend to improve as your body adjusts.